By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Eisai Inc. 

900 Davis Drive
P.O. Box 14505
Research Triangle Park  North Carolina  27709  U.S.A.
Phone: 919-941-6920 Fax: 919-941-6931


SEARCH JOBS
Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com.


Key Statistics


Email:
Ownership: Subsidiary

Web Site: Eisai Inc.
Employees: 2600
Symbol: ESALF.PK
 



Industry
Pharmaceutical






Company News
Oncodesign SA Has Entered Into A Services Agreement With Eisai Inc. (ESALF.PK) To Develop A New Personalized Medicine Program In Earlier Line Metastatic Breast Cancer Treatment 12/17/2014 11:44:28 AM
Eisai Inc. (ESALF.PK)'s David Martin Elected As National Pharmaceutical Council's Chairman Of The Board 11/7/2014 11:22:13 AM
Eisai Inc. (ESALF.PK) Announces FDA Acceptance Of Supplemental New Drug Application For Antiepileptic Drug Perampanel As Adjunctive Treatment Of Primary Generalized Tonic-Clonic Seizures 10/20/2014 9:02:51 AM
Eisai Inc. (ESALF.PK) Launches New Online Resource Helping Women Living With Metastatic Breast Cancer Navigate Their Journey 10/13/2014 11:35:08 AM
Eisai Inc. (ESALF.PK) Grabs FDA Approval For Chemotherapy Side Effect Drug AKYNZEO® 10/13/2014 7:10:19 AM
FDA Approves Eisai Inc. (ESALF.PK) Drug For Chemotherapy-Associated Nausea 10/10/2014 10:44:44 AM
Results Of Eisai Inc. (ESALF.PK) And Epilepsy Foundation National Survey Shed Light On Unmet Needs In Epilepsy Community 10/1/2014 9:26:07 AM
Eisai Inc. (ESALF.PK) And Arena Pharmaceuticals, Inc. (ARNA) Announce BELVIQ® (lorcaserin HCl) CIV Nominated A Second Time For The Prix Galien Award In The Best Pharmaceutical Agent Category 7/29/2014 8:04:43 AM
Eisai Inc. (ESALF.PK) & Helsinn Group To Present New CINV Research At 2014 International Symposium On Supportive Care In Cancer 6/26/2014 6:59:08 AM
Barry Lederman Appointed Vice President And Chief Financial Officer Of Eisai Inc. (ESALF.PK) 6/23/2014 8:11:48 AM
12345678910...
//-->